THE GREY
Regeneron Wants to Change What ‘Good’ Weight Loss Means
A bathroom scale is an extraordinarily crude scientific instrument. It cannot tell fat from muscle, fluid from tissue or healthy change from harmful change....
THE GREY
Lilly Found Another Way to Make Zepbound Stronger. The Side-Effect Bill Came Due.
The obesity-drug industry has developed a wonderfully seductive habit: whenever one hormone pathway works, add another one.
That strategy produced tirzepatide, which hits GIP and...
THE GREY
The Muscle-Loss Problem Just Became a Billion-Dollar Obesity Drug Opportunity
For the first act of the GLP-1 revolution, the scoreboard was brutally simple: how much weight came off? Every new drug presentation became a...
THE GREY
The Peptide Market Has a Transparency Problem—and Someone Finally Put a Number on It
“Third-party tested” may be the most overworked phrase in the research-peptide business.
It appears on homepages, product pages, badges, banners and social posts. It sounds...
THE GREY
The FDA’s Peptide Vote Is Back in the Headlines. Here’s the Part Everyone Keeps Getting Wrong.
The peptide internet has a favorite hobby: turning a complicated regulatory event into a victory graphic before anyone has finished reading the footnotes.
That is...
THE GREY
Roche Just Killed an Obesity Drug Once Tipped for Billion-Dollar Sales. This Is What a Gold Rush Looks Like Up Close.
Obesity drug development is often described as a gold rush, which sounds exciting until you remember what gold rushes actually look like: too many...
THE GREY
Lilly Says Its Pill Beats Novo’s Pill. There’s Just One Catch: They Never Faced Each Other.
The obesity market has become so competitive that companies no longer wait for their drugs to meet in the same clinical trial before declaring...
THE GREY
Novo Bets Up to $2.6 Billion on a Chinese Weight-Loss Pill. The Center of Gravity Is Moving East.
Novo Nordisk is betting up to $2.6 billion on HRS-1596, a once-weekly oral GLP-1/GIP candidate from China’s Hengrui. The deal signals how quickly China is becoming a source of next-generation obesity drugs.
